Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on KalVista Pharmaceuticals (KALV – Research Report), Bausch Health Companies (BHC – Research Report) and Insulet (PODD – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KalVista Pharmaceuticals (KALV)
In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on KalVista Pharmaceuticals, with a price target of $37.00. The company’s shares closed last Wednesday at $15.45, close to its 52-week high of $15.50.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $34.88.
See Insiders’ Hot Stocks on TipRanks >>
Bausch Health Companies (BHC)
In a report released today, Douglas Miehm from RBC Capital maintained a Hold rating on Bausch Health Companies, with a price target of $10.00. The company’s shares closed last Wednesday at $6.19.
According to TipRanks.com, Miehm is a 4-star analyst with an average return of
Bausch Health Companies has an analyst consensus of Hold, with a price target consensus of $7.75.
Insulet (PODD)
In a report released today, Lee Hambright from Bernstein maintained a Buy rating on Insulet, with a price target of $330.00. The company’s shares closed last Wednesday at $258.07.
According to TipRanks.com, Hambright is a 3-star analyst with an average return of
Currently, the analyst consensus on Insulet is a Strong Buy with an average price target of $363.24, implying a 36.6% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $285.00 price target.
